Teleflex Incorporated (NYSE: TFX), a leading global provider of
medical technologies, today announced results of its new survey
showing that symptoms of an enlarged prostate, also known as benign
prostatic hyperplasia (BPH), can interrupt travel plans and cause
other activities to be less enjoyable. Those surveyed indicated
that personal plans are often disrupted by urinary issues, and many
men pre-select specific routes on road trips due to bathroom
availability.
“Most men that come in for consultations believe bothersome
urinary symptoms are a common symptom of aging and have little
understanding of the options to alleviate the daily interruptions
those symptoms can cause. BPH is a common men’s health condition,
and more than 14 million men in the U.S. are seeking treatment for
it,”1 said David Wilkinson, M.D., a urologist and employee of
Teleflex.
BPH is non-cancerous enlargement of the prostate that occurs as
men age.2 The enlarged prostate presses on and can block the
urethra, causing lower urinary tract symptoms like increased
frequency or urgency of urination.3 BPH can result in interrupted
sleep, loss of productivity, depression, and decreased quality of
life.4
The Teleflex survey* was conducted to understand experiences men
have with urinary symptoms commonly associated with BPH. The survey
sample included approximately 1,000 men aged 45 years or older who
had at least one urinary symptom associated with BPH. Key findings
include:
- Approximately 1 in 4 men with at least one BPH symptom (23%)
report that they almost always choose certain routes on road trips
because they have more, or better, availability of bathroom
facilities.
- Nearly half of respondents (43%) report that they have to stop
more than they’d like to during road trips.
- 1 in 3 respondents (33%) “strongly agree” or “agree” with the
statement: “I used to enjoy road trips, but the frequent need to
urinate makes them less enjoyable.”
“Symptoms related to BPH can significantly impact quality of
life,” said Dr. Wilkinson. “I have had BPH patients who described
mapping out the nearest restrooms on road trips to seek
relief.”
All 1,000 men surveyed reported at least one symptom commonly
experienced with BPH, but only half of respondents (49%) have been
to a urologist, even though nearly all men surveyed (95%) reported
that it is important for them to be better informed about men’s
health issues.
“These survey findings emphasize the importance for men to seek
help from a urologist if they are experiencing unusual and
bothersome urinary symptoms,” said Kevin Hardage, president of the
Teleflex Interventional Urology business unit. “If BPH is left
untreated, it can lead to permanent bladder damage and worsen the
existing problem.”5
“In my experience, I’ve often seen men pay more attention to the
health of their cars than their own health. The survey results
underscore the need for more men to advocate for themselves and
visit a urologist to discuss their urinary symptoms and a
diagnostic evaluation such as cystoscopy, so that they can get back
on the road and back to enjoying their lives,” said Michael
Leventhal, executive director of the Men’s Health Network.
Men who are diagnosed with BPH are often prescribed medications
for the condition and may be unaware of other treatment options.
One such option is the UroLift™ System, a proven minimally invasive
treatment that can get men off BPH medications and allow them to
avoid major surgery.6 The UroLift™ System is the number one
minimally invasive BPH procedure chosen by urologists and their
patients in the U.S.1 Compared to medications, the UroLift™ System
has demonstrated a larger reported effect on quality of life for
patients.6,7
About the UroLift™
SystemThe UroLift™ System is a minimally invasive
treatment for lower urinary tract symptoms due to benign prostatic
hyperplasia (BPH). It is indicated for the treatment of symptoms of
an enlarged prostate up to 100cc in men 45 years or older (50 years
outside U.S.). The UroLift™ System permanent implants, which can be
delivered during an outpatient procedure,8 relieve prostate
obstruction without heating, cutting, destruction of, or removing
prostate tissue. The UroLift™ System can be used to treat a broad
spectrum of anatomies, including obstructive median lobe.9 It is
the only leading BPH procedure shown to not cause new onset,
sustained erectile or ejaculatory dysfunction.**3,6,10 A study
conducted over 5 years showed a low retreatment rate of about 2-3%
per year, or a total of 13.6% over the course of the study,
demonstrating UroLift™ System durability.6 Most common side effects
are temporary and can include hematuria, dysuria, micturition
urgency, pelvic pain, and urge incontinence.11 Rare side effects,
including bleeding and infection, may lead to a serious outcome and
may require intervention. Individual results may vary. The
prostatic urethral lift procedure (using the UroLift™ System) is
recommended for the treatment of BPH in both the 2021 American
Urological Association and 2022 European Association of Urology
clinical guidelines. More than 425,000 men have been treated with
the UroLift™ System in select markets worldwide.12 Learn more at
www.UroLift.com. Rx only.
About Teleflex IncorporatedTeleflex is a global
provider of medical technologies designed to improve the health and
quality of people’s lives. We apply purpose driven innovation – a
relentless pursuit of identifying unmet clinical needs – to benefit
patients and healthcare providers. Our portfolio is diverse, with
solutions in the fields of vascular access, interventional
cardiology and radiology, anesthesia, emergency medicine, surgical,
urology and respiratory care. Teleflex employees worldwide are
united in the understanding that what we do every day makes a
difference. For more information, please visit teleflex.com.
Teleflex is the home of Arrow™, Deknatel™, LMA™, Pilling™,
QuikClot™, Rüsch™, UroLift™ and Weck™ – trusted brands united by a
common sense of purpose.
Forward-Looking StatementsAny statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management’s current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which
may cause actual results or company actions to differ materially
from what is expressed or implied by these statements. These risks
and uncertainties are identified and described in more detail in
our filings with the Securities and Exchange Commission, including
our Annual Report on Form 10-K.
Teleflex, the Teleflex logo, Arrow, Deknatel, LMA, Pilling,
QuikClot, Rüsch, UroLift and Weck are trademarks or registered
trademarks of Teleflex Incorporated or its affiliates, in the U.S.
and/or other countries. All other trademarks are the property of
their respective owners. © 2023 Teleflex Incorporated. All rights
reserved. MAC02724-01 Rev A
References:
- U.S. 2022 estimates based on US Market Model 2022-24 (5-17-22
FINAL), which is in part based on Symphony Health PatientSource®
2018-21, as is and with no representations/warranties, including
accuracy or completeness
- American Cancer Society Key Statistics for Prostate Cancer
https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html#:~:text=The%20American%20Cancer%20Society's%20estimates,34%2C700%20deaths%20from%20prostate%20cancer
- AUA BPH Guidelines 2003, 2020
- Speakman, BJUI 2014
- Tubaro, Drugs Aging 2003
- Roehrborn, Can J Urol 2017
- Fwu, J Urol 2013
- Shore, Can J Urol 2014
- Rukstalis, Prostate Cancer and Prostatic Dis 2018
- McVary, Urology 2019
- Roehrborn, J Urology 2013
- Management estimate based on product sales as of April 2023.
Data on file Teleflex Interventional Urology.
*Content based on survey of approximately 1,000 US men, aged
45+, who have experienced at least one urinary symptom commonly
associated with an enlarged prostate (also known as benign
prostatic hyperplasia or BPH) conducted by Teleflex Interventional
Urology in 2023. Urinary symptoms may have multiple causes and
should only be diagnosed by a doctor. Sample sizes in this survey
may vary depending on qualifying questions.
**No instances of new, sustained erectile or ejaculatory
dysfunction in the L.I.F.T. pivotal study
Contacts:Teleflex Incorporated:Lawrence
KeuschVice President, Investor Relations and Strategy
DevelopmentInvestors.teleflex.com610-948-2836Media:Nicole
Osmernicole@healthandcommerce.com650-454-0504
Teleflex (NYSE:TFX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Teleflex (NYSE:TFX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024